| Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial O Hermine, X Mariette, PL Tharaux, M Resche-Rigon, R Porcher, ... JAMA internal medicine 181 (1), 32-40, 2021 | 906 | 2021 |
| Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial PL Tharaux, G Pialoux, A Pavot, X Mariette, O Hermine, M Resche-Rigon, ... The Lancet Respiratory Medicine 9 (3), 295-304, 2021 | 258 | 2021 |
| The 2023 ACR/EULAR antiphospholipid syndrome classification criteria M Barbhaiya, S Zuily, R Naden, A Hendry, F Manneville, MC Amigo, ... Arthritis & Rheumatology 75 (10), 1687-1702, 2023 | 227 | 2023 |
| Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA) B Bienvenu, KH Ly, M Lambert, C Agard, M Andre, Y Benhamou, ... La Revue de medecine interne 37 (3), 154-165, 2016 | 200 | 2016 |
| Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ... The Lancet 398 (10312), 1713-1725, 2021 | 191 | 2021 |
| Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results CM Yelnik, CA Laskin, TF Porter, DW Branch, JP Buyon, MM Guerra, ... Lupus science & medicine 3 (1), e000131, 2016 | 152 | 2016 |
| Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria M Barbhaiya, S Zuily, Y Ahmadzadeh, MC Amigo, T Avcin, ... Arthritis care & research 73 (10), 1490-1501, 2021 | 78 | 2021 |
| Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or … CM Yelnik, G Urbanski, E Drumez, V Sobanski, H Maillard, A Lanteri, ... Lupus 26 (2), 163-169, 2017 | 69 | 2017 |
| Non-stroke central neurologic manifestations in antiphospholipid syndrome CM Yelnik, E Kozora, S Appenzeller Current rheumatology reports 18, 1-9, 2016 | 67 | 2016 |
| The lupus anticoagulant paradox JE Molhoek, PG de Groot, RT Urbanus Seminars in Thrombosis and Hemostasis 44 (05), 445-452, 2018 | 52 | 2018 |
| Pulmonary arterial hypertension in idiopathic inflammatory myopathies: data from the French pulmonary hypertension registry and review of the literature S Sanges, CM Yelnik, O Sitbon, O Benveniste, K Mariampillai, ... Medicine 95 (39), e4911, 2016 | 52 | 2016 |
| Brief report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes CM Yelnik, TF Porter, DW Branch, CA Laskin, JT Merrill, MM Guerra, ... Arthritis & rheumatology 68 (8), 1964-1969, 2016 | 50 | 2016 |
| Ulnar artery occlusion and severity markers of vasculopathy in systemic sclerosis: a multicenter cross‐sectional study A Lescoat, CM Yelnik, G Coiffier, M Wargny, C Lamotte, C Cazalets, ... Arthritis & rheumatology 71 (6), 983-990, 2019 | 39 | 2019 |
| ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19 M Etienne, N Ettalhaoui, AG Everding, M Evers, I Fabre, M Fabre, ... Scientific data 9 (1), 454, 2022 | 38 | 2022 |
| The value of open-source clinical science in pandemic response: lessons from ISARIC A Abbas, SA Abdukahil, NN Abdulkadir, R Abe, L Abel, L Absil, S Acharya, ... The Lancet infectious diseases 21 (12), 1623-1624, 2021 | 37 | 2021 |
| Cognitive disorders and antiphospholipid antibodies CM Yelnik, E Kozora, S Appenzeller Autoimmunity reviews 15 (12), 1193-1198, 2016 | 37 | 2016 |
| Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial X Mariette, O Hermine, PL Tharaux, M Resche-Rigon, R Porcher, ... The Lancet Rheumatology 4 (1), e24-e32, 2022 | 36 | 2022 |
| High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry S Béliard, F Boccara, B Cariou, A Carrié, X Collet, M Farnier, J Ferrières, ... Atherosclerosis 277, 334-340, 2018 | 36 | 2018 |
| SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia A Gallo, S Charriere, A Vimont, MJ Chapman, D Angoulvant, F Boccara, ... Atherosclerosis 306, 41-49, 2020 | 35 | 2020 |
| Risk of pulmonary embolism more than 6 weeks after surgery among cancer-free middle-aged patients A Caron, N Depas, E Chazard, C Yelnik, E Jeanpierre, C Paris, ... JAMA surgery 154 (12), 1126-1132, 2019 | 35 | 2019 |
